The AHSA1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeted against the AHSA1 gene in the HeLa cervical adenocarcinoma cell line. This model enables functional dissection of the AHSA1 co-chaperone within the Hsp90 chaperone cycle. CRISPR-mediated gene disruption provides loss-of-function analysis of AHSA1, facilitating studies on protein folding, client maturation, and chaperone cycle regulation. The polyclonal nature yields a heterogeneous population suitable for population-level endpoint assays.
HeLa is an immortalized, HPV18-positive epithelial cell line derived from cervical adenocarcinoma. Widely used in cancer biology, HeLa cells exhibit robust growth, high transfectability, and well-characterized oncogenic signaling networks. Their transformed phenotype and continuous proliferation make them ideal for investigating chaperone-driven dependencies in a cancer-relevant setting. The AHSA1 knockout in this context directly addresses Hsp90 client protein regulation under inherent oncogenic stress.
AHSA1 encodes Aha1, a co-chaperone that binds Hsp90 and stimulates its ATPase activity, accelerating the chaperone cycle. This activity is critical for the stability and maturation of Hsp90 clients, including steroid hormone receptors (AR, ER), kinases (AKT, CDK4), mutant p53, and HIF-1??. AHSA1 interacts with co-chaperones HOP, p23, and FKBP52, and is transcriptionally regulated by HSF1 in response to stress. Disruption of AHSA1 impairs Hsp90 ATPase cycling, leading to proteasomal degradation of key clients and attenuation of oncogenic pathways.
HeLa cells rely on Hsp90 for maintaining the stability of numerous oncogenic clients such as AKT and mutant p53. AHSA1 knockout therefore provides a powerful model for examining the consequences of disrupted chaperone activity on cell proliferation, apoptosis, and stress signaling. The polyclonal population allows assessment of heterogeneous cellular responses and compensatory mechanisms, offering broader insights than clonal knockouts. This model is also well-suited for evaluating Hsp90 inhibitors in a background of impaired co-chaperone function.
This knockout panel is compatible with western blotting for client proteins (AKT, ER), Hsp90 ATPase activity assays, cell viability (MTT) and apoptosis (Annexin V) assays, co-immunoprecipitation, immunofluorescence, and RT-qPCR. Key applications include Hsp90 chaperone biology, cancer drug target validation, protein folding studies, and cellular stress response research. The product supports mechanistic inquiries into AHSA1 function and compound screening. For further information, contact Ascent Research.
